BML 4.91 Decreased By ▼ -0.06 (-1.21%)
BOP 13.13 Increased By ▲ 0.04 (0.31%)
CNERGY 7.04 Decreased By ▼ -0.14 (-1.95%)
CPHL 84.37 Decreased By ▼ -2.34 (-2.7%)
DCL 13.80 Decreased By ▼ -0.58 (-4.03%)
DGKC 170.74 Increased By ▲ 0.18 (0.11%)
FCCL 46.02 Decreased By ▼ -0.68 (-1.46%)
FFL 15.64 Decreased By ▼ -0.34 (-2.13%)
GCIL 26.09 Decreased By ▼ -0.55 (-2.06%)
HUBC 145.67 Decreased By ▼ -2.20 (-1.49%)
KEL 5.27 Decreased By ▼ -0.06 (-1.13%)
KOSM 6.36 Decreased By ▼ -0.14 (-2.15%)
LOTCHEM 20.65 Increased By ▲ 0.12 (0.58%)
MLCF 84.48 Decreased By ▼ -0.35 (-0.41%)
NBP 126.22 Decreased By ▼ -0.13 (-0.1%)
PAEL 41.79 Decreased By ▼ -1.46 (-3.38%)
PIAHCLA 22.03 Decreased By ▼ -0.59 (-2.61%)
PIBTL 8.73 Decreased By ▼ -0.24 (-2.68%)
POWER 13.89 Decreased By ▼ -0.13 (-0.93%)
PPL 165.47 Decreased By ▼ -3.29 (-1.95%)
PREMA 42.11 Decreased By ▼ -0.49 (-1.15%)
PRL 32.52 Decreased By ▼ -0.66 (-1.99%)
PTC 23.69 Decreased By ▼ -0.33 (-1.37%)
SNGP 116.55 Decreased By ▼ -2.01 (-1.7%)
SSGC 44.57 Decreased By ▼ -1.61 (-3.49%)
TELE 8.04 Decreased By ▼ -0.22 (-2.66%)
TPLP 10.00 Decreased By ▼ -0.38 (-3.66%)
TREET 23.08 Decreased By ▼ -0.84 (-3.51%)
TRG 56.79 Decreased By ▼ -1.28 (-2.2%)
WTL 1.52 Decreased By ▼ -0.03 (-1.94%)
BR100 13,779 Decreased By -75.9 (-0.55%)
BR30 39,619 Decreased By -569.5 (-1.42%)
KSE100 135,940 Decreased By -562.7 (-0.41%)
KSE30 41,374 Decreased By -178.9 (-0.43%)
World

WHO says awaits EMA, FDA reviews of J&J COVID-19 vaccine, monitoring global data

  • U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson's COVID-19 vaccine after six women under 50 given the shot developed rare blood clots.
Published April 13, 2021 Updated April 14, 2021

GENEVA: The World Health Organization, asked about reports of rare blood clots after vaccination with the Johnson & Johnson COVID-19 shot, told Reuters on Tuesday that it awaited reviews by the U.S. and European regulators and was monitoring global data.

"We're watching closely, waiting for EMA (European Medicines Agency) and FDA (U.S. Food and Drug Administration) reviews and monitoring the global database of adverse event reports to see if there have been cases anywhere else," the WHO said in an email reply. "It will take a little time to review the data."

U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson's COVID-19 vaccine after six women under 50 given the shot developed rare blood clots.

Following the news, J&J said it was delaying the rollout of the vaccine to Europe, a week after regulators there said they were reviewing rare blood clots in four recipients of the shot in the United States.

Comments

Comments are closed.